论文部分内容阅读
尽管研究者们在开发治疗最常见类型的肺癌-非小细胞肺癌(NSCLC)的疗法上已经取得了巨大的进步,但其它类型的肺癌依然可以躲避有效的疗法。近日一项刊登在国际杂志Clinical Cancer Research上的研究论文中,来自托马斯杰斐逊大学的研究人员通过对小鼠进行研究发现,利用两种实验性药物外加放射性疗法的三联疗法或许可以帮助治疗携带KRAS相关基因突变的癌症。研究人员Bo Lu博士表示,当前我们已经进行了相关的临床试验来评估癌症药物曲美替尼(trametinib)同药物palbociclib结合治疗实体瘤和黑色素瘤患者的效果;尽管未来在人类受试者中的研
Although researchers have made great strides in developing therapies for the treatment of lung cancer, the most common type of lung cancer, non-small cell lung cancer (NSCLC), other types of lung cancer can still evade effective therapy. In a recent research paper published in the journal Clinical Cancer Research, researchers from Thomas Jefferson University found that triple therapy with two experimental drugs plus radiotherapy may help treat KRAS-related Gene mutations in cancer. Dr. Bo Lu, a researcher, said that at present we have conducted relevant clinical trials to evaluate the effect of the combination of the trametinib cancer drug and the drug palbociclib in the treatment of solid tumors and melanoma patients; although in future, in human subjects research